Nov. 27, 2012
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. will sponsor a webinar on the "Promise of Alpha Therapy". The discussion will be broadcast and can be accessed via the link
November 30, 2012
and followed by questions and answers session from the audience. Participants will discuss their personal experience, both clinical and pre-clinical, with alpha particle immunotherapy platform-based drug candidates. The discussion is moderated by Dr.
and participants include Dr.
, Chairman, and Experimental Therapeutics Center at Memorial Sloan Kettering Cancer Center, Dr.
, Associate Attending Physician at
-Kettering's Department of Leukemia and Dr.
, Vice Chair for Research, Department of Radiology at Sloan Kettering.
The focus of the webinar is the use of alpha radioimmunotherapy in clinical trials and preclinical models. Dr. Scheinberg, who originated the idea of alpha immunotherapy, will discuss theoretical underpinnings of the approach and results of his preclinical experiments. Dr. Jurcic is currently treating acute myeloid leukemia (AML) patients in clinical trials with alpha immunotherapy drug candidates and he will present his experience and results. As a participant in clinical trials from the nuclear medicine side, Dr. Larson will provide a first-hand account on the ease of use and requirements for alpha immunotherapy. All participants will also offer their views on the future prospects of drugs based on this platform technology. The panel discussion to be broadcast on
3:00 PM Eastern Time
, questions for participants may be submitted via
or by phone, the details for which are as below:
Phone number: +1 (213) 493-0614Access Code: 157-776-237